Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CLS2901C

Phase 3Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoarthritis of the KneeRecruiting

Osteoarthritis of the KneePhase 3

Recruiting

Timeline

Expected Milestones

Q3 2031

Phase 3Recruiting

Osteoarthritis of the Knee

NCT06549686

Clinical

Trials by Indication[1]

Osteoarthritis of the Knee1 trial

A Phase III Study Evaluating the Efficacy and Safety of CLS2901C in Patients With Osteoarthritis of the Knee

Recruiting·CCellSeed Inc.·Phase 3·NCT06549686·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CLS2901C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLS2901C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLS2901C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CellSeed Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCellSeed Inc.

Related News